China Oncology ›› 2023, Vol. 33 ›› Issue (5): 499-505.doi: 10.19401/j.cnki.1007-3639.2023.05.010
• Article • Previous Articles Next Articles
WANG Hui1(), WANG Xia1, GAO Yi1, XU Jing1, YU Xiaojuan2, FAN Fangqin1, DING Yan1, KANG Yu1,3()
Received:
2022-12-09
Revised:
2023-04-27
Online:
2023-05-30
Published:
2023-06-16
Contact:
KANG Yu
CLC Number:
WANG Hui, WANG Xia, GAO Yi, XU Jing, YU Xiaojuan, FAN Fangqin, DING Yan, KANG Yu. Current status and influencing factors of gene screening in first-degree relatives of patients with hereditary breast-ovarian cancer syndrome[J]. China Oncology, 2023, 33(5): 499-505.
Tab. 1
Univariate analysis of patients’ basic characteristics and whether first-degree relatives received genetic screening [n (%)]"
Characteristic | Number of patients whose relatives have decided to undergo genetic screening (n=25) | Number of patients whose relatives have not decided to undergo genetic screening (n=42) | χ2/F value | P value |
---|---|---|---|---|
Age/year | 42.50±3.90 | 47.08±4.73 | 0.831 | 0.701 |
Time of illness/month | 7.20±0.73 | 9.03±1.34 | 0.763 | 0.301 |
Education level | 10.407 | <0.001 | ||
High school or below | 6 (24.00) | 28 (66.67) | ||
Junior college | 10 (40.00) | 10 (23.81) | ||
Bachelor degree or above | 9 (36.00) | 4 (9.52) | ||
Gene mutation type | 9.131 | 0.133 | ||
BRCA1 | 15 (60.00) | |||
BRCA2 | 10 (40.00) | |||
Disease type | 1.476 | 0.023 | ||
Breast cancer | 5 (20.00) | 10 (23.81) | ||
Ovarian cancer | 17 (68.00) | 30 (71.43) | ||
Breast cancer+ovarian cancer | 3 (12.00) | 2 (4.76) | ||
Staging of breast cancer | 0.764 | 0.062 | ||
Ⅰ-Ⅱ | 3 (37.50) | 7 (58.33) | ||
Ⅲ-Ⅳ | 5 (62.50) | 5 (41.67) | ||
FIGO staging of ovarian cancer | 2.143 | <0.001 | ||
Ⅰ-Ⅱ | 3 (15.00) | 13 (40.63) | ||
Ⅲ-Ⅳ | 17 (85.00) | 19 (59.38) |
Tab. 2
Univariate analysis of the first-degree relatives’ basic characteristics and whether received genetic screening[n (%)]"
Characteristic | Number of the first-degree relatives have decided to undergo genetic screening (n=102) | Number of the first-degree relatives have not decided to undergo genetic screening (n=214) | χ2/F value | P value |
---|---|---|---|---|
Age/year | 28.31±5.47 | 35.63±4.26 | 2.343 | 0.039 |
Gender | 3.564 | 0.011 | ||
Female | 62 (60.78) | 98 (45.79) | ||
Male | 40 (39.22) | 116 (54.21) | ||
Marital status | 0.876 | 0.342 | ||
Married | 79 (77.45) | 157 (73.36) | ||
Unmarried | 23 (22.55) | 57 (26.64) | ||
Divorce | 0 (0.00) | 0 (0.00) | ||
Education level | 2.083 | 0.039 | ||
High school or below | 11 (10.78) | 74 (34.58) | ||
Junior college | 48 (47.06) | 89 (41.59) | ||
Bachelor degree or above | 43 (42.16) | 51 (23.83) | ||
Career | 3.874 | 0.051 | ||
Administrative management | 14 (13.73) | 67 (31.31) | ||
Professional technology | 28 (27.45) | 51 (23.83) | ||
Education | 9 (8.82) | 21 (9.81) | ||
Business services | 17 (16.67) | 33 (15.42) | ||
Worker | 6 (5.89) | 2 (0.93) | ||
Individual | 21 (20.59) | 17 (7.94) | ||
Other | 7 (6.86) | 23 (10.75) | ||
Overall relationship score | 8.89±1.74 | 6.79±0.92 | 0.128 | 0.076 |
Intimacy score | 7.13±1.35 | 5.91±1.78 | 3.677 | 0.011 |
Communication frequency/month | 2.86±2.11 | 1.84±1.03 | 1.127 | 0.210 |
Communication methods | 0.492 | 0.676 | ||
Face to face | 33 (32.35) | 46 (21.50) | ||
Video | 49 (48.04) | 74 (34.58) | ||
Telephone | 20 (9.35) | 94 (43.93) | ||
Geographical distance | 12.452 | 0.061 | ||
Same city | 79 (77.45) | 97 (45.33) | ||
Different cities | 23 (22.55) | 117 (54.67) |
Tab. 3
Logistic regression analysis on whether first-degree relatives undergo genetic screening"
Argument | β | SE | χ2 value | P value | OR | 95% CI |
---|---|---|---|---|---|---|
Disease type | -0.862 | 0.125 | 1.353 | <0.001 | ||
FIGO staging of ovarian cancer | 2.336 | 0.853 | 0.431 | <0.001 | 0.262 | 0.071-0.729 |
Patient education level | ||||||
High school or below | 0.841 | 0.521 | 5.372 | 0.001 | 2.103 | 0.086-0.157 |
Junior college | -0.241 | 2.341 | 0.012 | 0.042 | 0.884 | 0.672-0.843 |
Bachelor degree or above | 1.109 | 0.852 | -2.731 | <0.001 | 0.104 | 0.075-0.932 |
Emotional intimacy | 0.436 | 0.071 | 4.871 | <0.001 | 0.267 | 0.075-0.822 |
Gender of the first-degree relatives | 1.031 | 0.325 | 6.931 | <0.001 | 4.217 | 1.691-10.554 |
Age of the first-degree relatives | -10.542 | 7.537 | -1.180 | 0.056 | 0.119 | 0.019-0.815 |
Education level of the first-degree relatives | ||||||
High school or below | 4.631 | 1.226 | 0.002 | |||
Junior college | -5.831 | 0.632 | 2.361 | <0.001 | 1.002 | 1.162-7.842 |
Bachelor degree or above | 15.324 | 8.102 | 0.731 | <0.001 | 0.031 | 0.015-0.743 |
[1] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
doi: 10.3322/caac.v68.6 |
[2] |
KUCHENBAECKER K B, HOPPER J L, BARNES D R, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23): 2402-2416.
doi: 10.1001/jama.2017.7112 |
[3] |
PUJADE-LAURAINE E, LEDERMANN J A, SELLE F, et al. Olaparib Tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9): 1274-1284.
doi: 10.1016/S1470-2045(17)30469-2 |
[4] | 郜意, 康玉, 徐丛剑. 遗传性卵巢癌风险评估和临床管理进展[J]. 中国实用妇科与产科杂志, 2020, 36(12): 1208-1213. |
GAO Y, KANG Y, XU C J. Progress in risk assessment and clinical management of hereditary ovarian cancer[J]. Chin J Pract Gynecol Obstet, 2020, 36(12): 1208-1213. | |
[5] |
YOUNG A L, BUTOW P N, RHODES P, et al. Talking across generations: family communication about BRCA1 and BRCA2 genetic cancer risk[J]. J Genet Couns, 2019, 28(3): 516-532.
doi: 10.1002/jgc4.v28.3 |
[6] | SEVEN M, SHAH L L, YAZICI H, et al. From probands to relatives: communication of genetic risk for hereditary breast-ovarian cancer and its influence on subsequent testing[J]. Cancer Nurs, 2022, 45(1): E91-E98. |
[7] | Practice bulletin No182: Hereditary breast and ovarian cancer syndrome[J]. Obstet Gynecol, 2017, 130(3): e110-e126. |
[8] | 中国抗癌协会肿瘤内分泌专业委员会, 中国优生科学协会女性生殖道疾病诊治分会, 中国优生科学协会肿瘤生殖学分会. 遗传性妇科肿瘤高风险人群管理专家共识(2020)[J]. 中国实用妇科与产科杂志, 2020, 36(9): 825-834. |
The Cancer Endocrine Professional Committee of the China Anti-Cancer Association, The Female Reproductive Disease Diagnosis and Treatment Branch of the China Eugenics Association. The Cancer Reproductive Science Branch of the China Eugenics Association. Expert consensus on management of high risk population of hereditary gynecological tumors (2020)[J]. Chin J Pract Gynecol Obstet, 2020, 36(9): 825-834. | |
[9] | HOLLANDS G J, FRENCH D P, GRIFFIN S J, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis[J]. BMJ, 2016, 352: i1102. |
[10] |
ALEGRE N, PERRE P V, BIGNON Y J, et al. Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among families with BRCA1/2 or MMR gene mutations[J]. Psychooncology, 2019, 28(8): 1679-1686.
doi: 10.1002/pon.v28.8 |
[11] |
GAFF C L, CLARKE A J, ATKINSON P, et al. Process and outcome in communication of genetic information within families: a systematic review[J]. Eur J Hum Genet, 2007, 15(10): 999-1011.
doi: 10.1038/sj.ejhg.5201883 pmid: 17609674 |
[12] |
TERCYAK K P, MAYS D, DEMARCO T A, et al. Decisional outcomes of maternal disclosure of BRCA1/2 genetic test results to children[J]. Cancer Epidemiol Biomarkers Prev, 2013, 22(7): 1260-1266.
doi: 10.1158/1055-9965.EPI-13-0198 |
[13] |
CHIVERS SEYMOUR K, ADDINGTON-HALL J, LUCASSEN A M, et al. What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research[J]. J Genet Couns, 2010, 19(4): 330-342.
doi: 10.1007/s10897-010-9296-y pmid: 20379768 |
[14] | 成小林, 李正东, 孙晓寅, 等. 乳腺癌患者血亲亲属对遗传咨询和基因检测意愿的调查[J]. 复旦学报(医学版), 2017, 44(3): 312-318. |
CHENG X L, LI Z D, SUN X Y, et al. Survey on the knowledge and willingness of genetic counseling and testing in blood relatives of breast cancer patients[J]. Fudan Univ J Med Sci, 2017, 44(3): 312-318. | |
[15] |
IRONS R F, CONTINO K M, HORTE J J, et al. Success of referral to genetic counseling after positive lynch syndrome screening test[J]. Int J Colorectal Dis, 2017, 32(9): 1345-1348.
doi: 10.1007/s00384-017-2849-x pmid: 28664346 |
[16] |
FAUST N, MULLER C, PRENNER J, et al. Low rates of genetic counseling and testing in individuals at risk for lynch syndrome reported in the national health interview survey[J]. Gastroenterology, 2020, 158(4): 1159-1161.
doi: S0016-5085(19)41896-9 pmid: 31816299 |
[17] |
HAN J, SPIGELMAN A D. Adherence to guidelines for the referral of patients with colorectal cancer and abnormal tumour tissue testing for assessment of Lynch syndrome[J]. ANZ J Surg, 2019, 89(10): 1281-1285.
doi: 10.1111/ans.15054 pmid: 30856687 |
[18] |
CHOPRA I, KELLY K M. Cancer risk information sharing: the experience of individuals receiving genetic counseling for BRCA1/2 mutations[J]. J Health Commun, 2017, 22(2): 143-152.
doi: 10.1080/10810730.2016.1258743 |
[19] | 王丹若, 袁玲, 武丽桂, 等. 肿瘤遗传风险人群对肿瘤遗传咨询的认知和态度[J]. 临床与病理杂志, 2018, 38(3): 575-583. |
WANG D R, YUAN L, WU L G, et al. Cognition and attitudes of cancer genetic risk groups to cancer genetic counseling[J]. J Clin Pathol Res, 2018, 38(3): 575-583. | |
[20] | 王雯邈. 中国人群MLH1表达缺失的结直肠癌林奇综合征筛查路径优化策略研究及筛查现状调查研究[D]. 北京: 北京协和医学院, 2020. |
WANG W M. Amodified screening strategy for Lynch syndrome among MLH1-deficient CRCs and genetic testing of Lynch Syndrome in China: survey of pathologists’ practice pattern and patients’ knowledge and willingness[D]. Beijing: Peking Union Medical College, 2020. | |
[21] | 中国抗癌协会大肠癌专业委员会遗传学组. 遗传性结直肠癌临床诊治和家系管理中国专家共识[J]. 实用肿瘤杂志, 2018, 33(1): 3-16. |
Genetics Group of the Committee of Colorectal Cancer,China Anticancer Association. The Chinese expert consensus on clinical diagnosis, treatment and pedigree management of hereditary colorectal cancer[J]. J Pract Oncol, 2018, 33(1): 3-16. | |
[22] |
MCGIVERN B, EVERETT J, YAGER G G, et al. Family communication about positive BRCA1 and BRCA2 genetic test results[J]. Genet Med, 2004, 6(6): 503-509.
doi: 10.1097/01.GIM.0000144014.91237.A1 |
[23] |
QUINN G P, VADAPARAMPIL S T, MIREE C A, et al. High risk men’s perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer[J]. Hum Reprod, 2010, 25(10): 2543-2550.
doi: 10.1093/humrep/deq207 |
[24] | Hereditary cancer syndromes and risk assessment: ACOG COMMITTEE OPINION, number 793[J]. Obstet Gynecol, 2019, 134(6): e143-e149. |
[25] | 吴潇, 赵卫东, 王慧妍, 等. 预防性输卵管-卵巢切除术对BRCA1和BRCA2突变携带者预防卵巢癌作用的系统评价[J]. 中国实用妇科与产科杂志, 2017, 33(8): 832-836. |
WU X, ZHAO W D, WANG H Y, et al. Systemic review and meta-analysis of the effect of risk-reducing salpingo oophorectomy on prevention of ovarian cancer in BRCA1 and BRCA2 mutation carriers[J]. Chin J Pract Gynecol Obstet, 2017, 33(8): 832-836. |
[1] | CHEN Luyan, WANG Lixue, FU Peifen. The value of surgery in the patients with de novo stage Ⅳ breast cancer [J]. China Oncology, 2023, 33(5): 431-436. |
[2] | YANG Wenxiao, GUO Linwei, LING Hong, HU Xin. Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy [J]. China Oncology, 2023, 33(5): 484-498. |
[3] | CHEN Junyao, ZHANG Wentao, LIU Qiao, NIE Jianyun. Clinical dilemma and systemic treatment strategy of triple-negative breast cancer in the elderly [J]. China Oncology, 2023, 33(5): 506-516. |
[4] | CHEN Hong, CHEN Junxia. Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(4): 342-353. |
[5] | BI Zhao, CHEN Peng, QIU Pengfei, CHEN Yuguang, WANG Yongsheng. The analysis of axillary lymph nodes metastasis after neoadjuvant therapy in breast cancer [J]. China Oncology, 2023, 33(4): 361-367. |
[6] | CAO Xiaoshan, CONG Binbin. The research progress of endocrine therapy combined with targeted therapy for triple-positive breast cancer [J]. China Oncology, 2023, 33(3): 288-292. |
[7] | SHAO Zhibo, YANG Benlong, WU Jiong. Progress of important clinical trials of breast cancer in China in 2022 [J]. China Oncology, 2023, 33(2): 103-109. |
[8] | ZHANG Huiqiang, JIANG Zefei. Key clinical studies on changing clinical practice of advanced breast cancer in 2022 [J]. China Oncology, 2023, 33(2): 110-116. |
[9] | ZHOU Changming, WANG Zezhou, ZHENG Ying. Interpretation of US cancer statistics 2023 and its implications for cancer prevention and treatment in China [J]. China Oncology, 2023, 33(2): 117-125. |
[10] | YANG Benlong, JIAO Dechuang, CHEN Jiajian, WANG Chunjian, JIN Lidan, ZHAO Wenhe, GAO Xueqiang, WANG Haibo, LI Jun, ZHAO Haidong, WU Di, FAN Zhimin, WANG Shujun, LIU Zhenzhen, WANG Yongsheng, WU Jiong. Compared the efficacy of mitoxantrone hydrochloride injection for tracing with radionuclide in sentinel lymph node biopsy of breast cancer [J]. China Oncology, 2023, 33(2): 126-133. |
[11] | DUAN Baowei, ZHAO Na, BI Zhao, QIU Pengfei, XU Xinghe, CHEN Yuguang, FAN Qingda, WANG Yongsheng. Radiotracer technique optimization for breast cancer internal mammary sentinel lymph node biopsy [J]. China Oncology, 2023, 33(2): 134-141. |
[12] | CHEN Yuguang, SUN Xiao, BI Zhao, QIU Pengfei, DUAN Baowei, FAN Qingda, WANG Yongsheng. Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation [J]. China Oncology, 2023, 33(2): 142-151. |
[13] | LENG Jie, QIU Guochun, ZHANG Bo, PU Yan. Mechanism of breast cancer centrosome regulatory protein SEC23B on tumor invasion and metastasis [J]. China Oncology, 2023, 33(2): 152-161. |
[14] | FAN Qingda, CONG Binbin, CHEN Yuguang, DUAN Baowei, WANG Yongsheng. Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients [J]. China Oncology, 2023, 33(2): 174-180. |
[15] | GUO Qing, ZHANG Jian. Advances in targeted therapy for HER2-low breast cancer [J]. China Oncology, 2023, 33(2): 181-190. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd